orf-blog.com
AUPH | Open Reading Frame
http://www.orf-blog.com/tag/auph
Skip to primary content. Skip to secondary content. Could gene therapy become biotech’s growth driver in 2017? July 4, 2016. Exelixis Renal cancer data are too good to ignore. August 2, 2015. As followers of this blog know, I have been a long term Exelixis ( EXEL. On Could gene therapy become biotech’s growth driver in 2017? On Could gene therapy become biotech’s growth driver in 2017? On Could gene therapy become biotech’s growth driver in 2017? Proudly powered by WordPress.
orf-blog.com
TRVN | Open Reading Frame
http://www.orf-blog.com/tag/trvn
Skip to primary content. Skip to secondary content. Biotech selloff leaves Wall Street disillusioned. January 18, 2016. Biotech portfolio updates Thoughts on ongoing correction and upcoming catalysts. August 22, 2015. Trevena Late stage innovation flying under the radar. July 19, 2015. Modest market cap ($264M) despite a positive clinical signal, an ongoing phase 2b and a potential FDA approval within three years. Continue reading →. Biotech portfolio update Sage, Marinus and Immunogen. June 14, 2015.
orf-blog.com
ESPR | Open Reading Frame
http://www.orf-blog.com/tag/espr
Skip to primary content. Skip to secondary content. Biotech catalysts for 2016. April 4, 2016. After last week’s pessimistic post, this week I am focusing on potential catalysts in 2016 that could improve sentiment towards biotech as a sector. As if to remind us late stage trials don’t always fail, last week saw positive news from three different programs, all of which are antibodies in non-oncology indications. Regeneron ( REGN. And its partner Sanofi ( SNY. Had positive P3 data for its PCSK9 program.
orf-blog.com
PCRX | Open Reading Frame
http://www.orf-blog.com/tag/pcrx
Skip to primary content. Skip to secondary content. Trevena Late stage innovation flying under the radar. July 19, 2015. Modest market cap ($264M) despite a positive clinical signal, an ongoing phase 2b and a potential FDA approval within three years. Continue reading →. On Could gene therapy become biotech’s growth driver in 2017? On Could gene therapy become biotech’s growth driver in 2017? On Could gene therapy become biotech’s growth driver in 2017? Proudly powered by WordPress.
orf-blog.com
Uncategorized | Open Reading Frame
http://www.orf-blog.com/category/uncategorized
Skip to primary content. Skip to secondary content. Could gene therapy become biotech’s growth driver in 2017? July 4, 2016. Notes from ASCO 2016. June 9, 2016. Although this year’s ASCO contained a limited amount of groundbreaking data, it provided some interesting take-aways and signaled important trends in oncology drug development. Below is my take on a quiet but important meeting. Immuno-oncology PD-1 combinations at their infancy. Biotech catalysts for 2016. April 4, 2016. After last week’s pessimi...
orf-blog.com
AERI | Open Reading Frame
http://www.orf-blog.com/tag/aeri
Skip to primary content. Skip to secondary content. Are biotech valuations sustainable? June 21, 2015. The biotech sector is currently in the most successful period in its history based on valuation metrics, amount of money raised and number of IPOs. The perception around the current situation ranges from very bearish (it’s a bubble) to very bullish (there’s enough innovation to fuel future growth). Esperion and Aerie Countdown to M&A. February 22, 2015. At first glance Esperion ( ESPR. And Aerie ( AERI.
orf-blog.com
Open Reading Frame | Analyzing biotech stocks | Page 2
http://www.orf-blog.com/page/2
Skip to primary content. Skip to secondary content. Newer posts →. ECC 2015 Renal cancer showdown between BMS and Exelixis. September 20, 2015. Biotech portfolio updates Thoughts on ongoing correction and upcoming catalysts. August 22, 2015. Exelixis Renal cancer data are too good to ignore. August 2, 2015. As followers of this blog know, I have been a long term Exelixis ( EXEL. Trevena Late stage innovation flying under the radar. July 19, 2015. Modest market cap ($264M) despite a positive clinical sign...
orf-blog.com
GEVA | Open Reading Frame
http://www.orf-blog.com/tag/geva
Skip to primary content. Skip to secondary content. Are biotech valuations sustainable? June 21, 2015. The biotech sector is currently in the most successful period in its history based on valuation metrics, amount of money raised and number of IPOs. The perception around the current situation ranges from very bearish (it’s a bubble) to very bullish (there’s enough innovation to fuel future growth). On Could gene therapy become biotech’s growth driver in 2017? On Could gene therapy become biotech’s growt...
SOCIAL ENGAGEMENT